Last reviewed · How we verify
vaginal DHEA 6.5 mg
Vaginal DHEA 6.5 mg, marketed by Angelica Lindén Hirschberg, holds a niche position in the treatment of specific gynecological conditions. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | vaginal DHEA 6.5 mg |
|---|---|
| Sponsor | Angelica Lindén Hirschberg |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women (PHASE4)
- Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors (PHASE2)
- Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer (PHASE3)
- A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy (PHASE3)
- Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia (PHASE4)
- Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain (PHASE3)
- Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) (PHASE3)
- Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vaginal DHEA 6.5 mg CI brief — competitive landscape report
- vaginal DHEA 6.5 mg updates RSS · CI watch RSS
- Angelica Lindén Hirschberg portfolio CI